Breaking News Instant updates and real-time market news.

SNY

Sanofi

$49.53

-0.06 (-0.12%)

, PFE

Pfizer

$35.83

-0.37 (-1.02%)

04:55
10/19/17
10/19
04:55
10/19/17
04:55

Drug Information Association to hold a conference

Metrics in Patient-Centered Drug Development Conference is being held in Rockville, MD on October 18-19.

SNY

Sanofi

$49.53

-0.06 (-0.12%)

PFE

Pfizer

$35.83

-0.37 (-1.02%)

ALKS

Alkermes

$51.09

-0.39 (-0.76%)

LLY

Eli Lilly

$85.73

-0.33 (-0.38%)

BMY

Bristol-Myers

$63.70

-0.48 (-0.75%)

  • 19

    Oct

  • 20

    Oct

  • 20

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 09

    Nov

  • 05

    Mar

SNY Sanofi
$49.53

-0.06 (-0.12%)

10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
Overweight
Regeneron, Sanofi overhang removed by court ruling, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that the U.S. Court of Appeals ruled in favor of Regeneron (REGN) and Sanofi (SNY) and vacated an injunction granted to Amgen (AMGN) to compel its competitors to pull Praluent from the market. While "this battle is far from over" and Raymond expects a new trial will be the next step, he also believes the ruling remove a significant marketing overhang that had hamstrung Regeneron and Sanofi sales reps. The analyst keeps an Overweight rating on Regeneron shares, which are currently halted with news pending.
10/11/17
BARD
10/11/17
NO CHANGE
Target $69
BARD
Outperform
AnaptysBio price target raised to $69 from $36 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio (ANAB) to $69 from $36 following positive proof-of-concept data for its anti-IL-33 antibody, adding that its scores look more impressive than Sanofi (SNY) and Regeneron's (REGN) initial data for atopic dermatitis for Dupixent. The analyst raised her price target to reflect the strong validation of its mechanism and Bitritto-Garg reiterated her Outperform rating on AnaptysBio shares.
08/30/17
08/30/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Sanofi (SNY) upgraded to Hold from Reduce at HSBC, with analyst Steve McGarry citing valuation. 2. M.D.C. Holdings (MDC) upgraded to Market Perform from Underperform at Wells Fargo with analyst Stephen East saying he sees "little reason the equity would move meaningfully lower" from current levels. 3. Ciena (CIEN) upgraded to Buy from Neutral at Citi with analyst Stanley Kovler saying the risk/reward is positive into third quarter results. 4. Six Flags (SIX) upgraded to Buy from Neutral at Hilliard Lyons with analyst Jeff Thomison citing improved valuation based on its 13% year-to-date pullback. 5. Prospect Capital (PSEC) upgraded to Market Perform from Underperform at Raymond James with analyst Robert Dodd saying he expects near-term earnings will cover the lower dividend run-rate but notes downside risk remains. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/17
FBCO
09/11/17
NO CHANGE
Target $485
FBCO
Outperform
Regeneron, Sanofi asthma trial 'statistically significant,' says Credit Suisse
Credit Suisse analyst Alethia Young notes that Regeneron (REGN)/Sanofi (SNY) released top-line asthma results, and the overall trial was "statistically significant." Specifically, the trial hit in the overall population, but it is unclear if the trial was statistically significant in the low eosinophil level patients alone, she notes. The analyst reiterates an Outperform rating and $485 price target on Regeneron's shares.
PFE Pfizer
$35.83

-0.37 (-1.02%)

10/12/17
DADA
10/12/17
NO CHANGE
Target $79
DADA
Buy
Pfizer announcement creates M&A opportunity for Prestige Brands,says DA Davidson
DA Davidson analyst Linda Bolton Weiser says Pfizer's (PFE) announcement that is is reviewing strategic alternatives for its $3.4B OTC drug business could create M&A opportunity down the road for Prestige Brands (PBH). If sold, the price tag could be over $10B, clearly too big for Prestige Brands, but the buyer could later sell some or all of the small brands, the analyst contended. With Prestige Brands continuing to de-lever its balance sheet and approaching the one year anniversary in January of its last deal, Weiser believes the company could within months announce an accretive acquisition. She reiterates a Buy rating and $79 price target on Prestige Brands shares.
09/20/17
09/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pfizer (PFE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he believes investors underappreciate the global prospects for breast cancer drug Ibrance, which he expects to maintain its first-to-market advantage. 2. Progressive (PGR) upgraded to Neutral from Underperform at Credit Suisse with analyst Ryan Tunis citing the announcement of much lower than expected Harvey losses of approximately $230M versus his estimate of $550M. 3. American Airlines (AAL) and Southwest (LUV) were upgraded to Outperform from Market Perform at Raymond James. 4. Post Holdings (POST) upgraded to Outperform from Market Perform at BMO Capital with analyst Kenneth Zaslow saying he expects the company to be boosted by egg price increases. 5. Nordson (NDSN) upgraded to Buy from Neutral at Longbow with analyst Christopher Dankert saying ATS growth concerns are overblown and views valuation as attractive. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
10/11/17
DBAB
10/11/17
NO CHANGE
Target $38
DBAB
Buy
Pfizer sale of consumer unit most likely option, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert believes a sale of Pfizer's Consumer Healthcare unit is the most likely outcome of the company's strategic review process. The analyst says he wouldn't be surprised if Pfizer has already received indications of interest in the business. A sale of the unit could be 3%-4% accretive depending on the price and assuming the company uses the proceeds to repurchase shares in order to offset dilution, Gilbert tells investors in a research note. He likes that management continues to explore strategic alternatives to increase shareholder value and keeps a Buy rating on Pfizer with a $38 price target.
ALKS Alkermes
$51.09

-0.39 (-0.76%)

10/16/17
LEHM
10/16/17
DOWNGRADE
Target $50
LEHM
Equal Weight
Alkermes downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Alkermes to Equal Weight and cut his price target for the shares to $50 from $66. The analyst has decreased conviction on Vivitrol sales trends over the next 12-24 months with "greater uncertainty facing state Medicaid programs in the current political environment." The sales are heavily reliant on policy initiatives which the company has little, if any, influence, Tsao tells investors in a research note. He also believes ALKS-5461 commercial success is priced into Alkermes shares at current levels.
07/27/17
LEER
07/27/17
NO CHANGE
Target $59
LEER
Market Perform
Leerink drops Alkermes depression drug approval odds to 40%
Leerink analyst Paul Matteis lowered his odds of approval for ALKS 5461, Alkermes' depression drug candidate, to 40% from 50% after the company learned that the FDA will be looking at MADRS-10 as the key assessment of efficacy, not MADRS-6, the primary endpoint in the FORWARD-5 trial. The analyst says he's now "incrementally more cautious on approvability." Matteis dropped his price target for Alkermes shares to $59 from $61 and reiterates a Market Perform rating on the name following the Q2 earnings report.
07/27/17
JEFF
07/27/17
NO CHANGE
Target $69
JEFF
Buy
Alkermes quarter in-line, focus now on ALKS 5461, says Jefferies
Jefferies analyst Biren Amin views Alkermes' Q2 results as in-line and says the focus now turns to initiating and completing the new drug application filing this for ALKS 5461 in depression. The analyst continues to see regulatory risk for ALKS 5461 and models a 50% discount rate to revenue estimates. Amin adds that Vivitrol and Aristada performed better in Q2. The analyst keeps a Buy rating on Alkermes with a $69 price target. Alkermes, which also disclosed this morning receipt of a subpoena from a U.S. Attorney regarding Vivitrol, is down 4% to $55.10 in afternoon trading.
06/30/17
COWN
06/30/17
NO CHANGE
Target $63
COWN
Outperform
Alkermes trial results 'solidly positive' despite some confusion, says Cowen
Cowen analyst Chris Shibutani says ALKS 3831 "cleared the efficacy bar" for new drug application filing in its first pivotal efficacy study. Importantly, 3831 also demonstrated similar efficacy to the olanzapine comparator arm, Shibutani tells investors in a research note. He expects 3831 to show its differentiated profile of reduced weight gain compared to olanzapine in the second pivotal weight study, expected in mid-2018. The analyst believes last night created some investor confusion, but points out the ENLIGHTEN-1 study was not designed to demonstrate any relative reduction in weight gain with ALKS 3831 versus olanzapine. He keeps an Outperform rating on Alkermes with a $63 price target. The shares in after-hours trading last night dropped 3% to $56.00.
LLY Eli Lilly
$85.73

-0.33 (-0.38%)

10/10/17
BMOC
10/10/17
NO CHANGE
Target $73
BMOC
Underperform
Eli Lilly to have good Q3, but concerns remain for FY19-20, says BMO Capital
BMO Capital analyst Alex Arfaei says Eli Lilly will have a good Q3, ending FY17 at the top end of guidance. However, Arfaei contends that longer-term concerns remain warranted because of price and volume erosion for insulin drug Humulin and slower growth of type-2 diabetes drug Jardiance. The analyst maintains his Underperform rating on Eli Lilly, raising his price target to $73 from $71.
10/10/17
10/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. HSBC (HSBC) downgraded to Underperform from Neutral at Credit Suisse with analyst Sanjay Jain citing valuation. 2. Jabil Circuit (JBL) downgraded to Sell from Neutral at Goldman Sachs with analyst Mark Delaney saying street expectations, which assume Jabil's earnings grow double digits year-over-year for both of the next two years, are overly optimistic. 3. Carlyle Group (CG) downgraded to Neutral from Buy at Citi with analyst William Katz citing valuation with the shares up 60% year-to-date. 4. Eli Lilly (LLY) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan saying the valuation looks full with the shares up 13% since mid-August. 5. Ralph Lauren (RL) downgraded to Sell from Hold at Miller Tabak. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/17
SBSH
10/18/17
UPGRADE
Target $72
SBSH
Buy
Merck upgraded to Buy from Neutral at Citi
Citi analyst Andrew Baum upgraded Merck (MRK) to Buy and raised his price target for the shares to $72 from $65. The healthcare giant closed yesterday down 12c to $63.22. While Merck's non-Keytruda business continues to erode, the market is undervaluing both the ultimate patient derived xenograft market size and Merck's likely market share with Keytruda, Baum tells investors in a research note. The analyst revised his initial PDx market estimates of $35bn to at least $50bn and increased his 2025 Keytruda forecasts from $9B to$15B. The analyst prefers Eli Lilly (LLY), Bristol-Myers (BMY) and Merck among the U.S. pharmaceutical majors. He also downgraded Roche (RHHBY) this morning to Neutral.
10/16/17
JEFF
10/16/17
NO CHANGE
Target $115
JEFF
Buy
Jefferies ups price target on top global pick AbbVie to $115
Jefferies analyst Jeffrey Holford keeps AbbVie (ABBV) as his top global Pharmaceuticals pick for October, followed by Roche (RHHBY), Novartis (NVS), Bayer (BAYRY), Johnson & Johnson (JNJ), Eli Lilly (LLY) and GlaxoSmithKline (GSK). The analyst raised his price target for AbbVie shares to $115 from $107 and keeps a Buy rating on the name. Among his other target changes include bumping Eli Lilly's to $100 from $96.
BMY Bristol-Myers
$63.70

-0.48 (-0.75%)

10/16/17
BMOC
10/16/17
UPGRADE
Target $71
BMOC
Outperform
Five Prime upgraded to Outperform on cabira prospects at BMO Capital
As previously reported, BMO Capital analyst M. Ian Somaiya upgraded Five Prime Therapeutics (FPRX) to Outperform from Market Perform and raised his price target to $71 from $39. Somaiya says he expects Phase I data to confirm the efficacy of cabira in 2L pancreatic cancer as superior to Bristol-Myers' (BMY) Onivyde at the upcoming SITC conference in November.
10/16/17
10/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Citi (C) downgraded to Sell from Hold at Societe Generale with analyst Andrew Lim citing the bank's third quarter earnings report. 2. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes its struggles will continue regardless of whether Marcato adds some of its people to the company's board. 3. Adobe (ADBE) downgraded to Hold from Buy at Deutsche Bank with analyst Nandan Amladi saying the valuation is "relatively full" with the shares up 50% year-to-date. 4. Ulta Beauty (ULTA) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Matthew Fassler saying recent data points, including a slowdown in Sephora U.S. sales and Bloomberg SpendTrend, suggest a more complicated path to recovery. 5. Bristol-Myers (BMY) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford saying the shares, following the recent rally, have "significant downside risk" should lung cancer trial CheckMate-227 fail. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/17
SBSH
10/18/17
NO CHANGE
Target $72
SBSH
Buy
Bristol-Myers price target raised to $72 from $55 at Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb to $72 saying the market "dramatically undervalues" the company's patient derived xenograft opportunity outside non-small cell lung cancer. The analyst's new price target reflects a contribution from CM-227 as well an acquisition premium of $7 per share. He keeps a Buy rating on Bristol-Myers.

TODAY'S FREE FLY STORIES

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated at First Analysis »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRE

Northstar Realty Europe

$14.20

0.05 (0.35%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Syndicate
Breaking Syndicate news story on Northstar Realty Europe »

Northstar Realty Europe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

FHN

First Horizon

$18.40

0.1 (0.55%)

, CBF

Capital Bank

$39.95

0.25 (0.63%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Hot Stocks
First Horizon, Capital Bank agree to sell two branches to Apex Bank »

First Horizon (FHN) and…

FHN

First Horizon

$18.40

0.1 (0.55%)

CBF

Capital Bank

$39.95

0.25 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$194.25

-0.75 (-0.38%)

16:32
11/17/17
11/17
16:32
11/17/17
16:32
Hot Stocks
Lennox executive sells 2,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TBNK

Territorial Bancorp

$30.99

0.21 (0.68%)

16:31
11/17/17
11/17
16:31
11/17/17
16:31
Hot Stocks
Territorial Bancorp declares special cash dividend of 30c per share »

Payable on December 20.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRTN

Triton International

$40.07

-0.77 (-1.89%)

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Hot Stocks
Triton International's Hanau sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Options
Preliminary option volume of 21.1M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.